表紙
市場調查報告書
商品編碼
977792

閹割抗性前列腺癌 (CRPC)的全球市場:市場規模·佔有率·趨勢分析,各部門預測 (各治療法·各地區)

Castrate-resistant Prostate Cancer Market Size, Share & Trends Analysis Report By Therapy (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiotherapy), By Region, And Segment Forecasts, 2020 - 2027

出版日期: | 出版商: Grand View Research, Inc. | 英文 90 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球閹割抗性前列腺癌治療的市場規模在2020年∼2027年間,預測將以8.4%的年複合成長率擴大,2027年之前達到162億美元。臨床試驗的進展和管道產品的推出將促進市場增長。

本報告提供全球閹割抗性前列腺癌 (CRPC) 治療的市場相關分析,彙整市場基本結構和主要的促進·阻礙因素,各治療法·各地區的市場趨勢預測 (今後8年份),主要企業的簡介與策略展開情形等資訊,為您概述為以下內容。

目錄

第1章 調查方法·範圍

第2章 摘要整理

第3章 閹割抗性前列腺癌 (CRPC) 市場:變動要素·趨勢·範圍

  • 市場關聯結構
  • 產品普及率·成長率預測:製圖
  • 用戶觀點分析
  • 法律規範
  • 市場動態
  • 閹割抗性前列腺癌:市場分析工具

第4章 閹割抗性前列腺癌市場:各治療法的估計值與趨勢分析

  • 市場定義和範圍
  • 市場佔有率分析:各治療法 (最新值·預測值)
  • 各治療法儀表板
  • 市場趨勢:各治療法 (實際成果值·預測值)
  • 市場規模與其預測,趨勢分析 (實際成果值·預測值)
    • 化療
    • 荷爾蒙療法
    • 免疫療法
    • 放射線治療

第5章 閹割抗性前列腺癌市場:各地區

  • 市場佔有率分析:各地區 (最新值·預測值)
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲

第6章 企業簡介

  • 主要企業最近的趨勢,對產業的影響
  • 主要企業的分類 (創新的企業,企業先驅,新企業)
  • 業者情勢
  • 上場公司
  • 未上市公司 (私人公司)
  • 企業簡介
目錄
Product Code: GVR-4-68039-237-3

Castrate-resistant Prostate Cancer Market Growth & Trends:

The global castrate-resistant prostate cancer market size is expected to reach USD 16.2 billion by 2027, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 8.4% from 2020 to 2027. This growth is driven by the rising global burden of castrate-resistant prostate cancer and unhealthy lifestyle.

In addition, the anticipated launch of new products and rising awareness of prostate cancer are likely to enhance the growth rate of the market over the forecast period. Moreover, the growing adoption of novel drugs and strong pipeline are factors likely to accelerate market growth during the forecast period.

The hormonal therapy segment dominated the market and held the largest revenue share of 83.1% in 2019. The segment is driven by increasing market penetration of Xtandi (enzalutamide) and the launch of Erleada (apalutamide) in the U.S., Europe, and Japan. Furthermore, the development and approval of an additional indication of Xtandi are driving the segment growth. In addition, immunotherapy is estimated to be the fastest-growing segment due to the presence of strong product pipeline drugs, which are projected to be launched during the forecast period.

North America's dominant share is attributable to high disease burden, technological advancements, proactive government measures, increased consumer awareness about the disease, and improvements in healthcare infrastructure. The presence of key players in this region is a key factor in boosting the growth of the market in the region. In addition, developing countries such as India and China are witnessing a high incidence of the disease that has resulted in an increase in the demand for improved therapeutics, an increase in healthcare expenditure, and a rise in government funding for oncology and other research activities. Thus, these factors are expected to drive the market in the Asia Pacific during the forecast period.

The presence of prominent players such as Sanofi; Johnson and Johnson Services, Inc.; Pfizer, Inc.; Astellas Pharma, Inc.; and Bayer AG in this market space significantly diminishes the opportunities of a new entry as it is difficult to match the high capital requirements. Key players are investing highly in the development of new molecules to maintain their presence in the market and acquire market share.

Castrate-resistant Prostate Cancer Market Report Highlights:

  • Prostate cancer is the highest prevalent cancer in men. 1 in 9 men are diagnosed with prostate cancer
  • Within 3 years of diagnosis, 10-50% of overall prostate cancer cases develop into metastatic castrate-resistant prostate cancer
  • The recommendation of products from healthcare authorities is expected to increase the sales of the drug, thereby fueling the market growth. For instance, Provenge is recommended by the Society for Immunotherapy of Cancer, the National Comprehensive Cancer Network, and the American Urological Association
  • Australia and New Zealand have the highest prevalence rate of the disease, followed by North America and Europe
  • In Asia Pacific, the market is likely to witness the fastest CAGR of 11.5% from 2020 to 2027

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources & third-party perspectives
    • 1.3.4. Primary research
  • 1.4. Information Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Data Visualization
  • 1.6. Data Validation & Publishing
  • 1.7. Model Details
  • 1.8. Commodity Flow Analysis
  • 1.9. Approach: Commodity Flow Approach
  • 1.10. List of Secondary Sources
  • 1.11. List of Abbreviations
  • 1.12. Objective
  • 1.13. Objective 1
  • 1.14. Objective 2
  • 1.15. Objective 3
  • 1.16. Objective 4

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Castrate-Resistant Prostate Cancer Market Variables, Trends & Scope

  • 3.1. Castrate-Resistant Prostate Cancer Market Lineage outlook
    • 3.1.1. Parent market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. User Perspective Analysis
  • 3.4. Regulatory Framework
  • 3.5. Market Dynamics
    • 3.5.1. Market driver analysis
      • 3.5.1.1. Rising prevalence of castrate-resistant prostate cancer
      • 3.5.1.2. Increasing technological advancements
      • 3.5.1.3. Rising adoption of treatment
    • 3.5.2. Market restraint analysis
      • 3.5.2.1. Lack of standard therapy
  • 3.6. Castrate-Resistant Prostate Cancer Market Analysis Tools
    • 3.6.1. Industry Analysis - Porter's
      • 3.6.1.1. Supplier Power
      • 3.6.1.2. Buyer Power
      • 3.6.1.3. Substitution Threat
      • 3.6.1.4. Threat from New Entrant
      • 3.6.1.5. Competitive Rivalry
    • 3.6.2. PESTEL Analysis
      • 3.6.2.1. Political Landscape
      • 3.6.2.2. Environmental Landscape
      • 3.6.2.3. Social Landscape
      • 3.6.2.4. Technology Landscape
      • 3.6.2.5. Legal Landscape

Chapter 4. Castrate-Resistant Prostate Cancer Market: Therapy Estimates & Trend Analysis

  • 4.1. Definitions & Scope
  • 4.2. Therapy Market Share Analysis, 2019 & 2027
  • 4.3. Therapy Dashboard
  • 4.4. Castrate-Resistant Prostate Cancer Market, By Therapy, 2016 to 2027
  • 4.5. Market Size & Forecasts and Trend Analyses, 2016 to 2027 for the following,
    • 4.5.1. Chemotherapy
      • 4.5.1.1. Chemotherapy market, 2016 - 2027 (USD Million)
    • 4.5.2. Hormonal Therapy
      • 4.5.2.1. Hormonal therapy market, 2016 - 2027 (USD Million)
    • 4.5.3. Immunotherapy
      • 4.5.3.1. Immunotherapy market, 2016 - 2027 (USD Million)
    • 4.5.4. Radiotherapy
      • 4.5.4.1. Radiotherapy market, 2016 - 2027 (USD Million)

Chapter 5. Castrate-resistant Prostate Cancer Market: Segment Analysis, By Region, 2016 - 2027 (USD Million)

  • 5.1 Castrate-resistant Prostate Cancer Market, Market Share by Region, 2019 & 2027
    • 5.1.1 North America
      • 5.1.1.1 North America market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.1.2 U.S.
      • 5.1.1.2.1 U.S. market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.1.3 Canada
      • 5.1.1.3.1 Canada market estimates and forecast, 2015 - 2027 (USD Million)
    • 5.1.2 Europe
      • 5.1.2.1 Europe market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.2.2 U.K.
      • 5.1.2.2.1 U.K. market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.2.3 Germany
      • 5.1.2.3.1 Germany market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.2.4 France
      • 5.1.2.4.1 France market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.2.5 Spain
      • 5.1.2.5.1 Spain market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.2.6 Italy
      • 5.1.2.6.1 Italy market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.2.7 Russia
      • 5.1.2.7.1 Russia market estimates and forecast, 2015 - 2027 (USD Million)
    • 5.1.3 Asia Pacific
      • 5.1.3.1 Asia Pacific market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.3.2 Japan
      • 5.1.3.2.1 Japan market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.3.3 China
      • 5.1.3.3.1 China market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.3.4 India
      • 5.1.3.4.1 India market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.3.5 South Korea
      • 5.1.3.5.1 South Korea market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.3.6 Singapore
      • 5.1.3.6.1 Singapore market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.3.7 Australia
      • 5.1.3.7.1 Australia market estimates and forecast, 2015 - 2027 (USD Million)
    • 5.1.4 Latin America
      • 5.1.4.1 Latin America market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.4.2 Brazil
      • 5.1.4.2.1 Brazil market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.4.3 Mexico
      • 5.1.4.3.1 Mexico market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.4.4 Argentina
      • 5.1.4.4.1 Argentina market estimates and forecast, 2015 - 2027 (USD Million)
    • 5.1.6 Middle East and Africa
      • 5.1.6.1 Middle East & Africa market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.6.2 South Africa
      • 5.1.6.2.1 South Africa market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.6.3 UAE
      • 5.1.6.3.1 UAE market estimates and forecast, 2015 - 2027 (USD Million)
      • 5.1.6.4 Saudi Arabia
      • 5.1.6.4.1 Saudi Arabia market estimates and forecast, 2015 - 2027 (USD Million)

Chapter 6. Company Profiles

  • 6.1. Recent developments & impact analysis, by key market participants
  • 6.2. Company/Competition Categorization (Key innovators, Market leaders, Emerging players)
  • 6.3. Public Companies
    • 6.3.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
    • 6.3.2. Competitive dashboard analysis
    • 6.3.3. Market differentiators
  • 6.4. Private Companies
  • 6.5. Company Profiles
    • 6.5.1. Sanofi
      • 6.5.1.1. Company Overview
      • 6.5.1.2. Financial Performance
      • 6.5.1.3. Product Benchmarking
      • 6.5.1.4. Strategic Initiatives
    • 6.5.2. Johnson & Johnson Services Inc.
      • 6.5.2.1. Company Overview
      • 6.5.2.2. Financial Performance
      • 6.5.2.3. Product Benchmarking
      • 6.5.2.4. Strategic Initiatives
    • 6.5.3. Pfizer Inc.
      • 6.5.3.1. Company Overview
      • 6.5.3.2. Financial Performance
      • 6.5.3.3. Product Benchmarking
      • 6.5.3.4. Strategic Initiatives
    • 6.5.4. Astellas Pharma, Inc.
      • 6.5.4.1. Company Overview
      • 6.5.4.2. Financial Performance
      • 6.5.4.3. Product Benchmarking
      • 6.5.4.4. Strategic Initiatives
    • 6.5.5. Bayer AG
      • 6.5.5.1. Company Overview
      • 6.5.5.2. Financial Performance
      • 6.5.5.3. Product Benchmarking
      • 6.5.5.4. Strategic Initiatives

List of Tables

  • TABLE 1 List of Secondary Sources
  • TABLE 2 List of Abbreviations
  • TABLE 3 Regulatory Framework
  • TABLE 4 Global Castrate-resistant Prostate Cancer Market, By Region, 2016 - 2027 (USD Million)
  • TABLE 5 Global Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 6 North America Castrate-resistant Prostate Cancer Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 7 North America Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 8 U.S. Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 9 Canada Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 10 Europe Castrate-resistant Prostate Cancer Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 11 Europe Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 12 U.K. Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 13 Germany Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 14 France Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 15 Spain Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 16 Italy Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 17 Russia Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 18 Asia Pacific Castrate-resistant Prostate Cancer Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 19 Asia Pacific Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 20 China Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 21 Japan Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 22 India Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 23 South Korea Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 24 Singapore Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 25 Australia Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 26 Latin America Castrate-resistant Prostate Cancer Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 27 Latin America Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 28 Brazil Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 29 Mexico Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 30 Argentina Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 31 MEA Castrate-resistant Prostate Cancer Market, By Country, 2016 - 2027 (USD Million)
  • TABLE 32 MEA Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 33 South Africa Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 34 UAE Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)
  • TABLE 35 Saudi Arabia Castrate-resistant Prostate Cancer Market, By Therapy, 2016 - 2027 (USD Million)

List of Figures

  • FIG. 1 Castrate-resistant Prostate Cancer Market Segmentation
  • FIG. 2 Market Research Process
  • FIG. 3 Information Procurement
  • FIG. 4 Primary Research Pattern
  • FIG. 5 Market Research Approaches
  • FIG. 6 Value-Chain-Based Sizing & Forecasting
  • FIG. 7 QFD Modeling for Market Share Assessment
  • FIG. 8 Market Formulation & Validation
  • FIG. 9 Castrate-resistant Prostate Cancer Market Snapshot
  • FIG. 10 Castrate-resistant Prostate Cancer Market Driver Impact
  • FIG. 11 Castrate-resistant Prostate Cancer Market Restraint Impact
  • FIG. 12 Penetration and Growth Prospect Mapping
  • FIG. 13 Porter's Five Forces Analysis
  • FIG. 14 SWOT Analysis, By Factor (Political & Legal Economic and Technological)
  • FIG. 15 Therapy Market Share Analysis, 2019 & 2027
  • FIG. 16 Therapy Dashboard
  • FIG. 17 Chemotherapy Market, 2016 - 2027 (USD Million)
  • FIG. 18 Hormonal Therapy Market, 2016 - 2027 (USD Million)
  • FIG. 19 Immunotherapy Derivatives Market, 2016 - 2027 (USD Million)
  • FIG. 20 Radiotherapy Market, 2016 - 2027 (USD Million)
  • FIG. 21 Castrate-resistant Prostate Cancer Market, Market Share by Region, 2019 & 2027
  • FIG. 22 North America
  • FIG. 23 North America Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 24 U.S.
  • FIG. 25 U.S. Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 26 Canada
  • FIG. 27 Canada Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 28 Europe
  • FIG. 29 Europe Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 30 U.K.
  • FIG. 31 U.K. Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 32 Germany
  • FIG. 33 Germany Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 34 France
  • FIG. 35 France Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 36 Spain
  • FIG. 37 Spain Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 38 Italy
  • FIG. 39 Italy Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 40 Russia
  • FIG. 41 Russia Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 42 Asia Pacific
  • FIG. 43 Asia Pacific Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 44 Japan
  • FIG. 45 Japan Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 46 China
  • FIG. 47 China Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 48 India
  • FIG. 49 India Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 50 South Korea
  • FIG. 51 South Korea Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 52 Singapore
  • FIG. 53 Singapore Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 54 Australia
  • FIG. 55 Australia Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 56 Latin America
  • FIG. 57 Latin America Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 58 Brazil
  • FIG. 59 Brazil Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 60 Mexico
  • FIG. 61 Mexico Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 62 Argentina
  • FIG. 63 Argentina Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 64 Middle East & Africa
  • FIG. 65 Middle East & Africa Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 66 South Africa
  • FIG. 67 South Africa Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 68 UAE
  • FIG. 69 UAE Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 70 Saudi Arabia
  • FIG. 71 Saudi Arabia Market Estimates and Forecast, 2016 - 2027 (USD Million)
  • FIG. 72 Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
  • FIG. 73 Competitive Dashboard Analysis
  • FIG. 74 Market Differentiators